NCT04050371View on ClinicalTrials.gov

Study of Truvada for HIV Pre Exposure Prophylaxis Using Daily Directly Observed Therapy to Look at Potential Interactions Between Truvada and Hormone Therapy

PHASE4CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

August 3, 2017

Primary Completion Date

May 23, 2018

Study Completion Date

May 23, 2018

Conditions
HIV PreventionTransgender Health
Interventions
DRUG

200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate

All study participants received daily observed therapy with FTC/TDF.

Trial Locations (1)

94103

San Francisco AIDS foundation, San Francisco

All Listed Sponsors
collaborator

San Francisco AIDS Foundation

OTHER

collaborator

California HIV/AIDS Research Program

OTHER

lead

University of California, San Francisco

OTHER

NCT04050371 - Study of Truvada for HIV Pre Exposure Prophylaxis Using Daily Directly Observed Therapy to Look at Potential Interactions Between Truvada and Hormone Therapy | Biotech Hunter | Biotech Hunter